Zymeworks的库存猛增8.5%,因为林业发展局批准新的肝癌治疗试验ZW251。 Zymeworks' stock jumps 8.5% as FDA approves trial for new liver cancer treatment ZW251.

一家生物技术公司Zymeworks Inc.在林业发展局批准测试ZW251之后,其库存增长了8.5%,这是对最常见的肝癌——肝细胞癌——的有希望的治疗方法。 Zymeworks Inc., a biotech company, saw its stock rise by 8.5% after the FDA approved its application to test ZW251, a promising treatment for hepatocellular carcinoma, the most common liver cancer. ZW251针对肝癌中常见的蛋白质,并在临床前期研究中显示出显著效果。 ZW251 targets a protein often found in liver cancer and showed strong results in preclinical studies. 今年,Zymeworks将开始第1阶段临床试验。 Zymeworks will begin Phase 1 clinical trials this year.